Clinical Trial: Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS

U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261072) titled 'Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS' on Nov. 20.

Brief Summary: Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c. every 2 weeks resulted in 42% to 45% of patients achieving a clinical response (HiSCR) to HS, and the efficacy was sustained through 52 weeks.However, we found in clinical practice that some HS patients present with localized lesions (small areas of involvement, affecting only 1-2 anatomic a...